Targets › PTPRC
8 programs from 8 companies in 9 trials: 6 Phase 1, 3 Phase 2; Oncology, Hematology, Other; next expected readout Dec 2026.
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. (UniProt, P08575)
Open in Phaseline: the race on PTPRC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Rabbit ATG Anti-thymocyte globulin; depletes T cells | PTPRC | Phase 2 | Refractory Idiopathic Aplastic Anemia | Jan 2027 |
| Northside Hospital, Inc. | Rabbit ATG Polyclonal anti-T cell antibody targeting T lymphocytes | PTPRC | Phase 2 | Severe Aplastic Anemia | Aug 2027 |
| Hong Kong Children's Hospital | CD45RA depleted DLI Donor lymphocyte infusion with CD45RA-positive cells depleted | PTPRC | Phase 2 | Hematopoietic Cell Transplantation | Oct 2029 |
| University Hospital, Geneva | CD45RA-depleted donor lymphocyte infusion (DLI) CD45RA-depleted T cell therapy - selective depletion of naive T cells expressing CD45RA an | PTPRC | Phase 1 | Hematologic Malignancy | Dec 2026 |
| Ruijin Hospital | CD45RA depleted donor lymphocyte infusion (DLI) CD45RA-depleted donor lymphocyte infusion; selective depletion of naive T cells via CD45RA | PTPRC | Phase 1 | Hematologic Malignancy | Jun 2027 |
| Fred Hutchinson Cancer Center | Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 Anti-CD45 monoclonal antibody labeled with radioactive astatine-211 | PTPRC | Phase 1 | Non-Malignant Neoplasm; Acute Lymphoblastic Leukemia in Remission | Jan 2028 |
| University Hospital Tuebingen | CD45RA depleted donor lymphocyte infusion (DLI) CD45RA depleted donor lymphocyte infusion after TCRα/β depleted haploidentical hematopoiet | PTPRC | Phase 1 | Hematologic Malignancy | Jan 2028 |
| Paul Szabolcs | CD45RA depleted leukocytes Negative selection depleting CD45RA+ naive T cells from donor bone marrow via CliniMACS im | PTPRC | Phase 1 | Sickle Cell Anemia | Aug 2028 |
Hematologic Malignancy (3) Severe Aplastic Anemia (1) Sickle Cell Anemia (1) Non-Malignant Neoplasm (1) Acute Lymphoblastic Leukemia in Remission (1) Hematopoietic Cell Transplantation (1) Refractory Idiopathic Aplastic Anemia (1)
protein or peptide (3), mixed (2), small molecule (1)
Northside Hospital, Inc. (1) Paul Szabolcs (1) Fred Hutchinson Cancer Center (1) Ruijin Hospital (1) Hong Kong Children's Hospital (1) University Hospital Tuebingen (1) Assistance Publique - Hôpitaux de Paris (1) University Hospital, Geneva (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.